PharmaCyte Biotech, Inc. - Recent Material Event

Item 304 of Regulation S-K promulgated under the Securities Exchange Act of 1934 (“Item 304”).


(b) On February 10, 2012, the Company engaged ROBISON, HILL & COMPANY as the Company's independent accountant to audit the Company’s financial statements and to perform reviews of interim financial statements.  During the fiscal years ended April 30, 2011 and 2010 and from April 30, 2011 through February 9, 2012 neither the Company nor anyone acting on its behalf consulted with ROBISON, HILL & COMPANY regarding (i) either the application of any accounting principles to a specific completed or contemplated transaction of the Company, or the type of audit opinion that might be rendered by ROBISON, HILL & COMPANY on the Company's financial statements; or (ii) any matter that was either the subject of a disagreement with M & K CPAS, PLLC or a reportable event with respect to M & K CPAS, PLLC.


ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.

Document

Location

16.1





Letter dated February 10, 2012, from M & K CPAS, PLLC to the Securities and Exchange Commission.

Filed herewith





SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



 

 

 

NUVILEX, INC.


(Registrant)

Date: February 15, 2012

By: /s/ Robert F. Ryan
 Robert F. Ryan, M.S., Ph.D.

  President and Chief Executive Officer
 (Principal Executive Officer On behalf of the Registrant)



 

 

 

 

 

 

 

 

2